UNII 1Q73Q2JULR

SODIUM CITRATE, UNSPECIFIED FORM

Unique Ingredient Identifier 1Q73Q2JULR is listed as a unspecified ingredient
NCITC62075
RXCUI253204

Alternate Names

Dosage Forms

UNII 1Q73Q2JULR SODIUM CITRATE, UNSPECIFIED FORM is commonly included in medications in the following forms.

RouteDosage FormPotency
INTRAVENOUSINJECTION0.37 %
ORALLIQUID12.5 mg/10mL
ORALSUSPENSION21.91 mg/1mL
AN,INFILTRATIONINJECTION0.04 %
AURICULAR (OTIC)SOLUTION2 %
AURICULAR (OTIC)SUSPENSION NA
EPIDURALINJECTION2.2 %
IM - IVINJECTABLE1.35 %
IM - IVINJECTION40 %
IM - IVPOWDER, FOR INJECTION SOLUTION3.5 %
IM - IVSOLUTION0.025 %
IM - IV - SCINJECTABLE0.23 %
IM - IV - SCINJECTION0.94 %
IM - SCINJECTION0.23 %
INHALATIONINHALANT NA
INHALATIONSOLUTION0.6 %
INHALATIONSUSPENSION, FOR INHALATION0.05 %
INTRA-ARTERIALINJECTION0.3 %
INTRA-ARTICULARINJECTION2.2 %
INTRACARDIACINJECTION0.8 %
INTRACAVITARYINJECTION0.15 %
INTRACAVITARYPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.005 %
INTRALESIONALINJECTION1 %
INTRAMUSCULARINJECTABLE0.435 %
INTRAMUSCULARINJECTION4 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION4.62 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.74 %
INTRAMUSCULARSOLUTION, INJECTION1.47 %
INTRAOCULARSOLUTION0.4 %
INTRAPERITONEALINJECTION2.2 %
INTRAPLEURALINJECTION ADJPH
INTRAPLEURALPOWDER, FOR INJECTION SOLUTION4.62 %
INTRASYNOVIALINJECTION1 %
INTRATHECALINJECTION ADJPH
INTRATHECALPOWDER, FOR INJECTION SOLUTION4.62 %
INTRATRACHEALSUSPENSION NA
INTRAUTERINESOLUTION0.32 %
INTRAVASCULARINJECTION0.32 %
INTRAVENOUSINFUSION ADJPH
INTRAVENOUSINJECTABLE20 %
INTRAVENOUSINJECTION1.64 MG/1ML
INTRAVENOUSINJECTION0.6 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION0.16 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED16.35 %
INTRAVENOUSSOLUTION0.83 %
IONTOPHORESISDRUG DELIVERY SYSTEM2.2 MG
IRRIGATIONINJECTION2.2 %
IV(INFUSION)INJECTABLE0.547 %
IV(INFUSION)INJECTION40 %
IV(INFUSION)INJECTION30 MG/100ML
IV(INFUSION)POWDER, FOR INJECTION SOLUTION8 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED14 %
IV(INFUSION)SOLUTION, CONCENTRATE2.4 %
IV(INFUSION)SOLUTION, INJECTION0.6 %
NASALGEL NA
NASALSOLUTION0.7 %
NASALSPRAY44 %
NASALSPRAY, METERED95.9 UG/SPRAY
NERVE BLOCKINJECTION0.04 %
OPHTHALMICPOWDER, FOR SOLUTION0.17 %
OPHTHALMICSOLUTION2.2 %
OPHTHALMICSOLUTION, DROPS2 %
OPHTHALMICSUSPENSION0.3 %
OPHTHALMICSUSPENSION, DROPS0.45 %
ORALCAPSULE1 MG
ORALCONCENTRATE5.07 MG/1ML
ORALDROPS100 MG/5ML
ORALEMULSION NA
ORALGRANULE210.63 MG/5ML
ORALGRANULE, FOR RECONSTITUTION0.7 MG
ORALGRANULE, FOR SUSPENSION15 MG
ORALLIQUID ADJPH
ORALPOWDER, FOR ORAL SUSPENSION40 MG/5ML
ORALPOWDER, FOR RECONSTITUTION2 MG/5ML
ORALPOWDER, FOR SOLUTION2942 MG/PACKET
ORALPOWDER, FOR SUSPENSION37.5 MG/5ML
ORALSOLUTION1567.5 MG/75ML
ORALSOLUTION ADJ PH
ORALSOLUTION, CONCENTRATE0.5 MG/1ML
ORALSOLUTION, ELIXIR22.5 MG/5ML
ORALSOLUTION, LIQUID7.09 MG/1ML
ORALSUSPENSION7800 MG/5ML
ORALSUSPENSION, EXTENDED RELEASE13 MG/5ML
ORALSUSPENSION, LIQUID0.9 MG/5ML
ORALSUSPENSION, SUSTAINED ACTION23.5 MG/1PKT
ORALSYRUP25 MG/5ML
ORALTABLET275 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE300 MG
ORALTABLET, COATED19 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED82 MG
ORALTABLET, EXTENDED RELEASE110 MG
ORALTABLET, FILM COATED200 MG
RECTALSOLUTION NA
RESPIRATORY (INHALATION)POWDER, FOR INHALATION0.14 %
RESPIRATORY (INHALATION)SUSPENSION, FOR INHALATION1 MG/2ML
SOFT TISSUEINJECTION1 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.74 %
SUBCUTANEOUSSOLUTION, INJECTION1.47 %
SUBLINGUALTABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL3.52 MG
TOPICALCREAM0.12 %W/W
TOPICALCREAM0.12 %W/W
TOPICALEMULSION, CREAM0.25 %W/W
TOPICALEMULSION, CREAM0.12 %W/W
TOPICALEMULSION, LOTION0.08 %W/W
TOPICALLOTION0.32 %W/W
TOPICALLOTION0.08 %W/W
TOPICALSHAMPOO2.6 %W/W
TOPICALSOLUTION1 MG/1ML
TOPICALSOLUTION0.1 %W/V
TOPICALSOLUTION, DROPS0.29 %W/V
TRANSDERMALDRUG DELIVERY SYSTEM2.2 MG
URETERALSOLUTION NA
VAGINALSPONGE7.6 MG

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.